New mRNA vaccine targets Hard-to-Treat lymphoma
NCT ID NCT07334574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a personalized mRNA vaccine (XP-006) for people with B-cell non-Hodgkin's lymphoma that has returned or not responded to treatment. The vaccine is custom-made to target each person's tumor. The main goal is to check safety and find the right dose, while also looking at how well it controls the disease. About 20 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••